Clinical

Dataset Information

0

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors


ABSTRACT: HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

DISEASE(S): Ovarian Cancer,Prostatic Neoplasms,Colorectal Cancer,Colorectal Neoplasms,Pancreatic Cancer,Ovarian Neoplasms,Breast Cancer,Prostatic Cancer

PROVIDER: 9330 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-09-18 | GSE218590 | GEO
2023-10-24 | PXD045033 | Pride
2012-09-30 | E-GEOD-35698 | biostudies-arrayexpress
2022-05-16 | GSE186086 | GEO
2022-05-16 | GSE186085 | GEO
2019-12-20 | GSE133941 | GEO
2020-12-02 | GSE150955 | GEO
2020-12-02 | GSE149104 | GEO
2019-11-12 | PXD011108 | Pride
| 2322588 | ecrin-mdr-crc